Cargando…
Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma
Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with met...
Autores principales: | Makino, Hirofumi, Notsu, Masakazu, Asayama, Itsuko, Otani, Hazuki, Morita, Miwa, Yamamoto, Masahiro, Yamauchi, Mika, Nakao, Mika, Miyake, Hitomi, Araki, Asuka, Uchino, Shinya, Kanasaki, Keizo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751735/ https://www.ncbi.nlm.nih.gov/pubmed/35370235 http://dx.doi.org/10.2169/internalmedicine.9261-21 |
Ejemplares similares
-
Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma
por: Morishita, Azusa, et al.
Publicado: (2022) -
Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism
por: Sakai, Mariko, et al.
Publicado: (2020) -
Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report
por: Roukain, Abdallah, et al.
Publicado: (2022) -
A case of insulin-like growth factor 2-producing gastrointestinal stromal tumor with severe hypoglycemia
por: Yamasaki, Haruka, et al.
Publicado: (2020) -
SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)